Hemogenyx Pharmaceuticals PLC Further re. Grant of Options (7514Z)
22 September 2020 - 9:52PM
UK Regulatory
TIDMHEMO
RNS Number : 7514Z
Hemogenyx Pharmaceuticals PLC
22 September 2020
22 September 2020
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Further re. Grant of Options
On 21 August 2020, the Company announced that the Directors had
granted the Company's co-founder and CEO Dr Vladislav Sandler
options over a total of 5,000,000 ordinary shares of 1p each in the
capital of the Company ("Share Options"). The Directors have now
resolved to adjust the exercise price of the Share Options to 9p to
reflect the Company's share price at the time of the grant. All
other details regarding the grant of the Share Options remain the
same.
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive
Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director peter.redmond@hemogenyx.com
Tel: +44 (0)20 3470
SP Angel Corporate Finance LLP 0470
Matthew Johnson, Vadim Alexandre,
Soltan Tagiev
Tel: +44 (0)20 7469
Peterhouse Capital Limited 0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
Notification and public disclosure of transactions by persons
discharging managerial responsibilities ("PDMR") and persons
closely associated with them ("PCA"):
1. Details of PDMR/person closely associated with them
a) Name Dr Vladislav Sandler
-------------------------- ---------------------------------------
b) Position/status CEO, Executive Director
-------------------------- ---------------------------------------
c) Initial notification/ Amendment to prior notification no.
amendment 00117904
-------------------------- ---------------------------------------
2. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description of Options over ordinary shares of 1p
the financial of Hemogenyx Pharmaceuticals plc
instrument Identification code GB00BYX3WZ24
-------------------------- ---------------------------------------
b) Nature of the Grant of options
transaction
-------------------------- ---------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) GBP0.09 5,000,000
----------
-------------------------- ---------------------------------------
d) Aggregated information Price(s) Volume(s)
- Aggregated N/A - variable 5,000,000
volume ----------
- Price
-------------------------- ---------------------------------------
e) Date of the transaction 20/08/2020
-------------------------- ---------------------------------------
f) Place of the Outside of a trading venue
transaction
-------------------------- ---------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHPPUBCBUPUGGP
(END) Dow Jones Newswires
September 22, 2020 07:52 ET (11:52 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024